Advitech Announces Positive Preclinical Results for Wound-Healing Application
QUEBEC CITY, Quebec, Oct. 10, 2007 /CNW Telbec/ - Advitech
Inc. ("Advitech" or the "Corporation") (TSX Venture Exchange:
AVI) today announced that two milk-derived protein extracts
from its XP-828L technological platform have demonstrated
wound-healing properties in an in vivo study conducted by
Dr. Charles Doillon of the Oncology and Molecular
Endocrinology Research Centre at the Centre Hospitalier de
l'Université Laval (CHUL). Dr. Doillon is a recognized
researcher in the field of wound healing and angiogenesis.
The study has demonstrated that both protein extracts could
significantly impact the wound-healing response, especially
the formation of regenerated collagen fibre and its
remodelling in wound
"The data further confirms the bio-activity of our protein extracts and brings new opportunities for Advitech. The results suggest that these two products act early in the healing process and would accelerate wound-healing without excessive long-term remodelling", stated Dr. Christina Juneau, Vice-President, Research and Development. "Three potential fields of application have been identified", added Dr. Juneau:
1. The management of skin ulcers, particularly pressure ulcers;
2. The improvement of scar tissue response in plastic and reconstructive surgery and dermabrasion;
3. The acceleration of the healing process in burn wounds.
"Part of our 2007 business plan focuses on the identification of
new commercial opportunities targeting dermatological
applications, with additional revenues for the 2008 fiscal
year", stated Renaud Beauchesne, president and CEO at
Advitech. "With these positive results regarding
wound-healing applications, we have achieved an additional
milestone in our plan, while developing our natural growth
factor based technological platform with respect to natural
growth factors", commented Mr.
According to Espicom Business Intelligence Ltd., the global wound care market totalled $7.2 billion in 2006, with a 10% growth rate. Growth factor based applications for wound-healing represent more than 5% of the market, with an impressive 27% growth rate.
Posted: October 2007